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Abstract. Yinchenhao decoction (YCHD) is a traditional 
Chinese medicine formulation, which has been widely used 
for the treatment of jaundice for 2,000 years. Currently, YCHD 
is used to treat various liver disorders and metabolic diseases, 
however its chemical/pharmacologic profiles remain to be eluci-
dated. The present study identified the active compounds and 
significant pathways of YCHD based on network pharmacology. 
All of the chemical ingredients of YCHD were retrieved from the 
Traditional Chinese Medicine Systems Pharmacology database. 
Absorption, distribution, metabolism and excretion screening 
with oral bioavailability (OB) screening, drug‑likeness (DL) 
and intestinal epithelial permeability (Caco-2) evaluation 
were applied to discover the bioactive compounds in YCHD. 
Following this, target prediction, pathway identification and 
network construction were employed to clarify the mechanism 
of action of YCHD. Following OB screening, and evaluation 
of DL and Caco‑2, 34 compounds in YCHD were identified 
as potential active ingredients, of which 30 compounds were 
associated with 217 protein targets. A total of 31 significant 
pathways were obtained by performing enrichment analyses of 
217 proteins using the JEPETTO 3.x plugin, and 16 classes of 
gene-associated diseases were revealed by performing enrich-
ment analyses using Database for Annotation, Visualization 
and Integrated Discovery v6.7. The present study identified 
potential active compounds and significant pathways in YCHD. 
In addition, the mechanism of action of YCHD in the treatment 
of various diseases through multiple pathways was clarified.
Introduction
Yinchenhao decoction (YCHD) is a classical traditional 
Chinese medicine (TCM) formulation. YCHD has been 
used widely for the treatment of Yang jaundice and liver 
disorders. YCHD is composed of three Chinese medicinal 
herbs: Artemisiae scopariae herba (ASH, Yinchen), Radix et 
Rhizoma Rhei (RERR, Dahuang) and Gardeniae Fructus (GF, 
Zhizi). Pharmacologic studies have shown that this formula-
tion can also be used to treat pancreatic carcinoma (1), liver 
injury (2,3), liver fibrosis (4), liver cirrhosis (5,6), nonalco-
holic steatohepatitis (7), cholestasis (8) and diabetes mellitus 
(DM) (9).
In recent years, TCM monomers and TCM compounds have 
been studied extensively worldwide. Liu et al (10) predicted 
the molecular targets of YCHD based on systems-biology 
methods using the TCMGeneDIT database. However, only 
17 main compounds were analyzed, and no active component 
in GF was identified (11). Other studies have focused only on 
the molecular mechanism of a certain aspect of YCHD, for 
example, immunity and metabolism, transport, signal transduc-
tion, and cell growth/proliferation (12). Previously, we found 
that genipin, a single component of GF, had inhibitory effects 
on human hepatocellular carcinoma cells (13). However, the 
active substances of YCHD and its specific molecular mecha-
nism of action in the diseases mentioned above are not clear.
Any TCM formulation is a complex system with multiple 
components, multiple targets, and synergistic interactions 
among its components (14). Because of its complex chemical 
composition, it is extremely difficult to study its role in the 
body as a mixture. The complexity of TCM formulations 
makes their in‑depth study difficult, whereas systems pharma-
cology provides new ideas and perspectives for the study of 
Chinese herbal compounds. Studies on the active substances 
of TCM formulations, identification of the targets of active 
components, and determination of the relationship between 
efficacious substances and diseases using systems pharma-
cology (15) and network pharmacology (16) can help elucidate 
the molecular mechanism of action of TCM formulations.
For Chinese herbal compounds administered via the oral 
route, the ingredients in a TCM formulation must first over-
come the barriers posed by ADME (absorption, distribution, 
metabolism and excretion) processes, and only the molecules 
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that pass through the barriers may be classed as ‘active mole-
cules’ (17). These molecules bind to the targets in the body, 
thereby eliciting their actions. Then, drugs interact with the 
human body at the network level, as well as the overall level 
of the organ.
Therefore, based on analyses of ADME-related properties, 
identification of the active molecules in TCM formulations 
that pass across the body barrier and prediction of the network 
targets of active substances was undertaken. Thereafter, studies 
on the overall effect on the body, as well as the mechanism of 
action, was carried out. This strategy could provide a basis for 
in-depth understanding of the mechanism of action of TCM 
formulations. The workflow of the network‑pharmacology 
approach in the present study is illustrated in Fig. 1.
Materials and methods
Identification of candidate compounds. All compounds of the 
three Chinese medicinal herbs in YCHD were collected from 
the Traditional Chinese Medicine Systems Pharmacology 
Database and Analysis Platform (TCMSP) database. The 
TCMSP database consists of 500 Chinese herbal medicines 
registered in the Chinese Pharmacopoeia (2010 edition) with 
30,069 ingredients through literature mining and database 
integration. Data relevant to the pharmacokinetic properties 
of each chemical compound, which contained the prediction 
of oral bioavailability (OB), intestinal epithelial permeability 
(Caco‑2 cells), drug‑likeness (DL), blood‑brain barrier (BBB), 
drug half‑life (HL) and Lipinski's rule (LR) of five, were 
provided for the screening and evaluation of compounds (17).
Screening of active compounds. In ADME processes, OB is 
one of the most important pharmacokinetic parameters (18). 
High OB is often a key indicator to determine the DL of bioac-
tive molecules. For TCM formulations, the failure of most of 
the ingredients to reach the protein target sites of particular 
cells is due to a lack of appropriate pharmacologic properties, 
especially OB. Molecules with OB ≥30% were considered to 
have good OB in the present study.
In the early stages of drug development, DL evaluation 
helps to screen out excellent compounds (19) and increases the 
‘hit rate’ of drug candidates. Therefore, the DL of molecules 
in YCHD was assessed using the Tanimoto coefficient in the 
present study (20) using the following formula:
Where x is the molecular descriptor of YCHD based on Dragon 
software (http:www.talete.mi.it/products/dragon_descrip-
tion.htm) and y is the average descriptor of all drugs in the 
Drugbank database. The average DL Index of all drugs in the 
Drugbank database is 0.18, which indicates a high DL. Thus 
in our study, active molecules were defined as those with a DL 
Index ≥0.18.
The intestinal epithelial permeability can be investigated 
using Caco-2 cells (21). Orally administered drugs are absorbed 
mainly through intestinal epithelial cells. Therefore, simula-
tion of drug transport across the monolayers of small-intestinal 
epithelial cells is crucial for the prediction of drug absorption. 
The permeability of epithelial cells of ingredients in Chinese 
herbal medicines was predicted using the TCMSP database. It 
was considered that molecules with Caco-2 >-0.40 had good 
permeability in the small-intestinal epithelium.
Hence, the selected candidate molecules had to meet the 
requirements of OB ≥30%, DL ≥0.18 and Caco‑2 >‑0.40 for 
further analyses.
Identification of associated proteins and gene names. Protein 
targets were retrieved from the TCMSP database (http://lsp.
nwsuaf.edu.cn/tcmsp.php). The dataset used in model-building 
comprised 6511 drug molecules and 3987 targets for which 
the compound‑protein interactions are known in the Drugbank 
database (17). UniProt Knowledgebase (UniProtKB) is a 
protein database containing 54,247,468 sequence entries. 
The gene names were extracted further from the UniProtKB 
(http://www.uniprot.org).
Identification of significant pathways and gene‑associated 
diseases. Java Enrichment of Pathways Extended to Topology 
(JEPETTO) is a Cytoscape 3.x plugin that performs inte-
grative analyses of human gene sets. It can also identify 
functional associations between genes and known cellular 
pathways and processes using protein‑interaction networks 
and topologic analyses (22). Significant pathways can 
be identified by enrichment analyses of proteins using 
JEPETTO. Analyses of gene-associated diseases were 
performed with acquired genetic information by the Database 
for Annotation, Visualization and Integrated Discovery 
(DAVID) v6.7 (23).
Construction of a network and analyses. The Compound-Target 
Network was built by connecting the candidate compounds 
and corresponding targets. The Compound‑Pathway Network 
was generated by linkage of the candidate compounds and the 
signaling pathways involved. In the Gene‑Disease Network, 
diseases were connected with the associated candidate targets. 
The corresponding diseases of potential genes were collected 
by DAVID enrichment analyses, and the obtained interactions 
between diseases and genes were applied further for building 
the Gene‑Disease Network.
In this bilateral network, the ‘nodes’ represented the 
compounds, protein targets, signal pathways or diseases, and 
‘edges’ represented the interactions of Compound-Target, 
Compound‑Pathway or Gene‑Disease. The networks were 
constructed using Cytoscape v3.3.0 (24).
Results
Identification of the active compounds in YCHD. Using the 
TCMSP database, 236 compounds were retrieved: 53 in ASH, 
92 in RERR, and 98 in GF (3 herbs shared 7 compounds). The 
network flowchart of the compounds in YCHD is shown in 
Fig. 1. Of the 53 compounds in ASH, 34 satisfied the criterion 
of OB ≥30%, and 13 satisfied the criteria of OB ≥30%, DL ≥0.18 
and Caco‑2 ≥‑0.4. Of the 92 compounds in RERR, 26 satisfied 
the criterion of OB ≥30%, 16 satisfied the criteria of OB ≥30% 
and DL ≥0.18, and 9 satisfied the criteria of OB ≥30%, DL 
≥0.18 and Caco‑2 ≥‑0.4. Of the 98 compounds in GF, 43 satis-
fied the criterion of OB ≥30%, and 15 satisfied the criteria of 
OB ≥30% and DL ≥0.18, and 14 satisfied the criteria of OB 
MOLECULAR MEDICINE REPORTS  16:  4583-4592,  2017 4585
≥30%, DL ≥0.18 and Caco‑2 ≥‑0.4. Among 243 compounds, 
36 compounds satisfied all of the pre‑defined requirements 
(Table I) and, finally, 33 compounds were analyzed after 
removing duplicates. The OB of genipin was <30%, but it was 
a common compound in GF and was shown to have inhibi-
tory effects on human hepatocellular carcinoma cells in our 
previous study (13). Hence, genipin was also regarded to be a 
candidate compound. The details of 34 compounds are shown 
in Table II. Interestingly, all three Chinese medicinal herbs in 
YCHD (i.e., ASH, RERR and GF) contained beta-sitosterol, 
whereas RERR and GF contained quercetin. Beta-sitosterol 
and quercetin are the common chemicals found in 188 TCM 
formulations according to the TCMSP database.
Identification of targets in YCHD. Among the 34 compounds 
obtained, 618 proteins and genes were obtained for 
30 compounds, and 217 proteins and genes were included 
after removing duplicates. The 30 candidate compounds 
and all of the potential targets were applied to produce a 
plot of Compound-Target interactions, including 247 nodes 
(30 compounds and 217 targets) and 618 edges (Fig. 2). In 
Fig. 2, the red nodes are drug targets and the blue nodes are 
compounds, and the edges represent the interactions between 
them. The centralization and heterogeneity of the network 
was 0.603 and 2.355, respectively. This finding indicated 
that some nodes were more concentrated in the network 
than others. That is, the Compound-Target space was biased 
towards certain compounds and targets. As depicted in Fig. 2, 
MOL053 (quercetin) displayed the most target interactions 
(degree=154), followed by MOL173 (kaempferol, degree=63), 
MOL015 (beta-sitosterol, degree=38), MOL014 (isorhamnetin, 
degree=37) and MOL174 (stigmasterol, degree=31).
A TCM formulation is a complex system with various 
components; one component may act on multiple targets and 
display synergistic effects to treat diseases. These compounds 
with high degree nodes may perform important roles in 
the pharmacologic effect of YCHD. Protein targets acting 
as ‘hubs’ in the network were prostaglandin G/H synthase 
2 (PTGS2; 28 interactions), heat‑shock protein HSP 90 
(20 interactions), prostaglandin G/H synthase 1 (19 
interactions), nuclear receptor coactivator 2 (18 interactions), 
dipeptidyl peptidase IV (18 interactions) and mRNA of PKA 
catalytic subunit C-alpha (17 interactions).
Revealing the significant pathways. Enrichment analyses of 
217 proteins were done using JEPETTO and 31 significant 
pathways were obtained (Table III). This XD-score is rela-
tive to the average distance to all pathways and represents a 
deviation (positive or negative) from the average distance. The 
q‑value determines the significance of the overlap (Fisher's 
exact test) between the input information and the pathways. 
The Overlap/Size shows the number of overlapping proteins 
compared with the size of the pathway.
Enrichment algorithm analyses of the XD-score and q-value 
revealed the highest XD-score to be 1.47032, and the threshold 
value of XD-score in our study was 0.35. Eighteen disease path-
ways included 11 cancer pathways (non-small-cell lung cancer, 
small-cell lung cancer, bladder cancer, prostate cancer, endo-
metrial cancer, colorectal cancer, glioma, pancreatic cancer, 
chronic myeloid leukemia, acute myeloid leukemia, mela-
noma) and one immune system-disease pathway (graft-vs.-host 
disease), three infectious disease-related pathways (leishmani-
asis, malaria, Chagas disease), two neurodegenerative-disease 
pathways (prion diseases, amyotrophic lateral sclerosis) 
and one metabolic-disease pathway (type-II DM). Thirteen 
signaling pathways included four pathways involved in the 
immune system (NOD‑like receptor, Toll‑like receptor, Fc 
epsilon RI, B cell receptor), two signal-transduction pathways 
(ErbB, vascular endothelial growth factor (VEGF) ), two cell 
growth and death pathways (p53 signaling pathway, apoptosis), 
three endocrine-system pathways (progesterone-mediated 
oocyte maturation, gonadotropin-releasing hormone (GnRH) 
signaling pathway, adipocytokine signaling pathway) and one 
lipid-metabolism pathway (biosynthesis of steroid hormone). 
The Compound‑Pathway network was constructed with 
29 candidate compounds and their significant pathways 
Table I. The number of compounds in YCHD satisfy OB≥ 
30%, DL≥0.18 and Caco‑2≥‑0.4
Herbs Total OB≥ 30% DL≥0.18 Caco‑2≥‑0.4
ASH 53 34 (64.2) 13 (24.5) 13 (24.5)
RRER 92 26 (28.3) 16 (17.4) 9 (9.8)
GF 98 43 (48.9) 15 (15.3) 14 (14.3)
YCHD, yinchenhao decoction; OB, oral bioavailability; DL, 
drug‑likeness.
Figure 1. The workflow for the network‑pharmacology approach used in our 
study.
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Table II. Information for candidate active compounds from ASH, RRER and GF herbs.
Number Molecule name OB (%) Caco‑2 DL Molecular structure Herb
MOL014 Isorhamnetin 49.6 0.31 0.31  ASH
MOL015 Beta-sitosterol 36.91 1.32 0.75  ASH/RRER/GF
MOL020 Areapillin 48.96 0.6 0.41  ASH
MOL024 Genkwanin 37.13 0.63 0.24  ASH
MOL028 Skrofulein 30.35 0.72 0.3  ASH
MOL030 Isoarcapillin 57.4 0.4 0.41  ASH
MOL031 Eupalitin 46.11 0.62 0.33  ASH
MOL032 Eupatolitin 42.55 0.16 0.37  ASH
MOL034 Capillarisin 57.56 0.49 0.31  ASH
MOL036 4'‑Methylcapillarisin 72.18 0.57 0.35  ASH
MOL037 Demethoxycapillarisin 52.33 0.31 0.25  ASH
MOL038 Artepillin A 68.32 0.45 0.24  ASH
MOL053 Quercetin 46.43 0.05 0.28  ASH/GF
MOL065 Eupatin 50.8 0.53 0.41  RRER
MOL081 Mutatochrome 48.64 1.97 0.61  RRER
MOL098 Rhein 47.07 -0.2 0.28  RRER
MOL111 Toralactone 46.46 0.86 0.24  RRER
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Table II. Continued.
Number Molecule name OB (%) Caco‑2 DL Molecular structure Herb
MOL127 Daucosterol_qt 35.89 1.35 0.7  RRER
MOL133 Palmidin A 32.45 -0.36 0.65  RRER
MOL138 Aloe-emodin 83.38 -0.12 0.24  RRER
MOL143 (-)-catechin 49.68 -0.03 0.24  RRER
MOL144 Crocetin 35.3 0.54 0.26  GF
MOL145 Genipin 26.06 -0.37 0.10  GF
MOL146 (4aS,6aR,6aS,6bR, 32.03 0.61 0.76  GF
 8aR,10R,12aR,
 14bS)-10-hydroxy
 -2,2,6a,6b,9,9,
 12a-heptamethyl-1,3,
 4,5,6,6a,7,8,8a,10,11,
 12,13,14b-
 tetradecahydropicene-
 4a-carboxylic acid
MOL147 Ammidin 34.55 1.13 0.22  GF
MOL156 Sudan III 84.07 0.42 0.59  GF
MOL173 Kaempferol 41.88 0.26 0.24  GF
MOL174 Stigmasterol 43.83 1.44 0.76  GF
MOL196 Mandenol 42 1.46 0.19  GF
MOL198 Supraene 33.55 2.08 0.42  GF
MOL212 Isoimperatorin 45.46 0.97 0.23  GF
MOL216 Ethyl oleate (NF) 32.4 1.4 0.19  GF
MOL217 5-hydroxy-7-methoxy-2- 51.96 0.88 0.41  GF
 (3,4,5-trimethoxyphenyl) 
 chromone
MOL229 3‑Methylkempferol 60.16 0.37 0.26  GF
OB, oral bioavailability; DL, drug‑likeness.
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included 60 nodes (29 compounds and 31 pathways) and 
468 edges (Fig. 3). Pathways are represented by pink nodes, 
compounds are represented by blue nodes, and the interac-
tions between them are represented by edges in Fig. 3. 
Centralization and heterogeneity of the network was 0.273 
and 0.533, respectively. It was found that the VEGF signaling 
pathway (degree=28) was linked with 28 chemical molecules, 
and that other pathways interacted with at least two molecules.
Revealing gene‑associated diseases. A Gene‑Disease network 
was constructed to identify the potential targets of diseases in 
which different compounds act upon (Fig. 4). In the present 
study, 160 potential targets were found which were associated 
with 16 classes of diseases. Ninety-six genes were related to 
cancer, 87 genes were related to metabolism, 81 genes were 
related to cardiovascular diseases, and 81 genes were related to 
the immune system. Among 160 genes, there were 42 common 
targets in four diseases: Cancer, metabolic, cardiovascular 
and immune. The 42 common targets genes were ADH1C, 
ADRB2, AR, CCL2, COL1A1, CRP, CYP1A1, CYP1A2, 
CYP3A4, EGF, ESR1, ESR2, F2, GSTM1, GSTP1, HMOX1, 
ICAM1, IFNG, IGF2, IL10, IL1A, IL1B, IL6, INSR, MMP1, 
MMP2, MMP9, MPO, NOS2, NOS3, PLAU, PON1, PPARG, 
PTGS2, SELE, SERPINE1, SLC6A4, SPP1, TGFB1, TNF, 
TP53, and VEGFA. Among 160 genes, GSTM1, NOS3, and 
TNF were common genes of 16 diseases.
Taken together, these results indicate that YCHD can regu-
late whole-body systems through a complex genes-interaction 
network, resulting in a certain effect in various diseases.
Discussion
TCM formulations are composed of multiple ingredients. 
Their mechanism of action is complex, and may be associated 
Figure 2. Compound‑Target network for YCHD. The red nodes represent potential drug targets and the blue nodes represent active compounds. The edges 
represent the interaction between them and the node size is proportional to the degree.
MOLECULAR MEDICINE REPORTS  16:  4583-4592,  2017 4589
with multiple targets and multiple pathways. YCHD is a classic 
TCM formulation and used commonly to treat liver diseases by 
clearing heat, eliminating dampness, and removing jaundice.
In the present study, we proposed a network pharmacologic 
approach to identify bioactive compounds and significant 
pathways in YCHD by OB screening, as well as evaluation 
of DL and intestinal absorption. Finally, 243 compounds 
in YCHD were extracted from the TCMSP database, and 
33 compounds with good OB, DL and small-intestinal absorp-
tion were considered to be active molecules in YCHD for 
further study.
Some of the compounds have been shown to possess 
pharmacologic activities for the treatment of various 
diseases. These include the anti-lung-cancer activity of 
isorhamnetin (25), as well as beta-sitosterol (analgesic) (26), 
genkwanin (anti‑colorectal cancer) (27), eupalit in 
(anti-prostate carcinoma) (28), capillarisin (anti-hyperalgesic 
and anti-allodynic) (29), quercetin (anticancer) (30), rhein 
(anticancer) (31), aloe-emodin (anti-growth disorders) (32), 
crocetin (anticancer) (33), Sudan III (anti-persistent chylous 
ascites) (34), kaempferol (anti‑pancreatic cancer) (35), stig-
masterol (anticancer) (36). In our study, based on the potential 
targets that 34 compounds act upon, 31 significant pathways 
and 16 classes of diseases that were associated with the targets 
were obtained.
By analyzing the topologic proper t ies of the 
Compound‑Target interaction network, we found that 
compounds with high degree nodes and protein targets that 
occupied hub positions in the network could perform impor-
tant roles in the pharmacologic function of YCHD. Analyses of 
the Compound‑Pathway network showed that the main active 
ingredients in YCHD could act on multiple pathways, and that 
the TCM formulations had multiple components, multiple 
targets and integrated regulation (14). Then, we linked poten-
tial genes to diseases, and found that these potential genes 
were related to several complex diseases: Cancer, cardiovas-
cular, metabolic, and immune. For example, the development 
and progression of tumors is associated with multiple path-
ways (37,38). The main advantage of TCM therapeutics is 
that the many compounds within them exert a more robust 
Table III. The 31 significant pathways found by JEPETTO.
Number Pathway  XD-score q-value Overlap/size
  1 Bladder cancer 1.47032 0.00000 16/38
  2 Non-small cell lung cancer 1.08065 0.00000 16/51
  3 Prostate cancer 1.02555 0.00000 26/84
  4 Pancreatic cancer 1.01321 0.00000 22/70
  5 Endometrial cancer 0.94804 0.00000 14/50
  6 Colorectal cancer 0.79509 0.00000 18/61
  7 Metabolism of xenobiotics by cytochrome P450 0.77843 0.00045 6/20
  8 Glioma 0.76675 0.00000 16/60
  9 Leishmaniasis 0.6752 0.00000 17/62
10 Steroid hormone biosynthesis 0.64509 0.00931 4/15
11 Type II diabetes mellitus 0.62494 0.00003 10/43
12 NOD‑like receptor signaling pathway 0.61233 0.00000 14/59
13 Prion diseases 0.607 0.00004 9/35
14 Small cell lung cancer 0.57843 0.00000 20/82
15 ErbB signaling pathway 0.56917 0.00000 17/84
16 VEGF signaling pathway 0.56409 0.00000 14/62
17 Chronic myeloid leukemia 0.53594 0.00000 16/69
18 Malaria 0.53081 0.00003 10/42
19 Acute myeloid leukemia 0.52287 0.00003 11/52
20 Chagas disease 0.51782 0.00000 22/99
21 p53 signaling pathway 0.49646 0.00000 15/62
22 Toll‑like receptor signaling pathway 0.47843 0.00000 19/90
23 Melanoma 0.46367 0.00003 12/62
24 Apoptosis 0.44093 0.00000 17/81
25 Progesterone-mediated oocyte maturation 0.41387 0.00002 14/79
26 Fc epsilon RI signaling pathway 0.41091 0.00023 11/65
27 B cell receptor signaling pathway 0.40613 0.00002 13/69
28 Graft-versus-host disease 0.37843 0.01012 5/25
29 GnRH signaling pathway 0.37629 0.00003 14/83
30 Adipocytokine signaling pathway 0.3679 0.00036 10/57
31 Amyotrophic lateral sclerosis (ALS) 0.36104 0.00007 10/47
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Figure 3. Compound‑Pathway network for YCHD. The pink nodes represent significant pathways and the blue nodes represent active compounds. The edges 
represent the interaction between them and node size is proportional to the degree.
Figure 4. Gene‑Disease network for YCHD. The red nodes represent disease and the pink nodes represent genes. The edges represent the interaction between 
them and node size is proportional to the degree.
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synergistic effect than any individual compound by ‘hitting’ 
multiple targets. Therefore, the multidirectional mechanisms 
of TCM formulations that act through multiple pathways of 
the immune system, endocrine system, signal transduction and 
cell growth and death may offer a new therapeutic tool to treat 
tumors.
Studies have shown that the active molecules in YCHD 
include beta-sitosterol (39), isorhamnetin (25), genkwanin (27), 
eupalitin (28) and quercetin (30) and have anticancer effects. In 
particular, quercetin is a potent antioxidant flavonoid found in 
many common medicinal herbs, and possesses a wide spectrum 
of biologic activities (40). Quercetin may have cardioprotective, 
anticancer, anti‑ulcer, anti‑allergic, anti‑viral, anti‑inflamma-
tory, anti-DM, gastroprotective, anti-hypertensive, anti-infective 
and immunomodulatory activities (41). Our network study also 
showed that YCHD can act on cancer, metabolic, cardiovascular, 
and immune systems. Disease enrichment analyses showed 
that 96 genes were related to cancer. Pathway enrichment 
analyses demonstrated YCHD to be involved with regula-
tion of multiple pathways in cancer, including apoptosis (1) as 
well as various signaling pathways: NOD‑like receptor (42), 
Toll‑like receptor (43), Fc epsilon RI (44), B-cell receptor (45), 
ErbB (46), VEGF (47), and GnRH (48). Therefore, YCHD 
may exert anticancer effects through regulation of cell death, 
anti‑inflammation, anti‑immune system, anti‑angiogenesis, and 
energy metabolism (37). Our study also verified a report stating 
that YCHD has pharmacologic activities against primary liver 
cancer (49), pancreatic carcinoma (1), and DM (9).
In most cases, the occurrence and development of a disease 
can also be considered to be a result of a network (50,51). 
Interestingly, we found 42 common targets in four diseases 
(cancer, metabolic, cardiovascular, and immune) among 
160 genes. We also showed that a disease does not occur in 
isolation. Studies using a one-target and one-drug model tend to 
ignore the relationship between diseases (52). The constituents 
of TCM formulations are complex, and the effect that a single 
component produces may be relatively weak. However, these 
ingredients with different effects and different targets can act 
on various aspects of the disease through systems, and they 
interact with each other to produce synergistic effects (53,54). 
Network pharmacology can be used to predict the target profiles 
and pharmacologic actions of herbal compounds. In our study, 
network‑construction approaches were applied to identify 
bioactive compounds and potential targets and to determine the 
underlying mechanism of action of YCHD. However, additional 
experiments must be carried out to validate our study results.
Thirty-four bioactive compounds with 31 significant 
pathways in YCHD were identified by performing network 
analyses, which explains how to treat disease through multiple 
components, targets and pathways. The method of network 
pharmacology developed in our study could provide novel 
insights into the mechanism of action of YCHD.
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